Reuters logo
BRIEF-Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease
September 1, 2017 / 3:19 AM / 21 days ago

BRIEF-Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease

Sept 1 (Reuters) - Sosei Group Corp

* Says co’s unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study

* Says unit will receive $15 million milestone payment under a global R&D and commercialisation partnership announced in April 2016

Source text in Japanese: goo.gl/GiYgfQ

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below